DaVita is Secretly Trying to Defend its Charity Scheme with a Lobbying Scheme

Published on Read Report

GET OUR LATEST REPORTS DELIVERED TO YOUR INBOX

Genworth: We See Almost No Chance Of Regulatory Approval. This Deal Would Be A Disaster For Policyholders

Published on

Ladenburg: Near-Term Headwinds And Unsustainable Balance Sheet Engineering Ladenburg Thalmann Financial Services Inc. (LTS)

Published on

Opko Health: If These SEC Charges Were Surprising Then You Haven’t Been Paying Attention OPKO Health, Inc. (OPK)

Published on

Apollo Medical: Look Out Below – Russell’s Latest Float Calculation Screw-Up Apollo Medical Holdings, Inc. (AMEH)

Published on

We Believe Genprex Is A Disaster In The Making Genprex, Inc (GNPX)

Published on

Inpixon: If This Sketchy Deal Is Legal The Public Markets May Be In Deep Trouble Inpixon (INPX)

Published on

Pulse Biosciences: Failed FDA Clearance, New SEC Investigation, And An Uncertain Path Forward Pulse Biosciences (PLSE)

Published on

Aphria Insiders Disclose Stake In Nuuvera’s Initial Financing Round Just 1 Day Before Expected Deal Closing Aphria Inc. (APHQF)

Published on

Could Rampant Red Flags Drown Aphria’s Proposed Nuuvera Acquisition? Aphria Inc. (APHQF)

Published on

Crius Energy Trust: An Unsustainable Collision Course Crius Energy Trust (CRIUF)

Published on